BridgeBio Pharma, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
BridgeBio Pharma, Inc. (BBIO) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$153.83 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-24
- BridgeBio Pharma, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$153.83M.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$113.86M.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$137.11M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$153.83M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$113.86M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$137.11M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |